-
In a Phase 3, randomized clinical trial of primary systemic therapy for patients with early, locally advanced breast cancer, the addition of capecitabine to each of six 3-weekly cycles of epirubicin-docetaxel resulted in a 1.64 fold increase in the possibility of primary tumor pathologic complete response.
-
In a Phase 2 trial, Ludwig and colleagues present data on 79 patients with relapsed or refractory myeloma who were treated with bendamustine in combination with bortezomib and dexamethasone.
-
Patients with progressive advanced esophagogastric adenocarcinoma treated with docetaxel in addition to active symptom control (ASC) survived 44% longer than those who received ASC alone.
-
In a Phase 2 study, Ahmadi and colleagues demonstrate reasonably high response rates in rituximab-resistant indolent lymphoma patients sequentially treated with lenalidomide/dexamethasone (Part 1; 2 monthly cycles) followed by lenalidomide/dexamethasone + weekly rituximab (Part 2; 3 monthly cycles).
-
-
There is new evidence that initiating palliative care consults in the ED results in shorter hospital lengths of stay (LOS).
-
WellCare Health Plans is partnering with community-based organizations that provide social safety net services to provide a diabetes management program for its members.
-
Through Capital District Physicians' Health Plan's medication therapy management program, pharmacists in the community and embedded in large primary care practices work with patients to help them adhere to their treatment plan.
-
Women presenting for emergency contraception were offered a copper IUD or Plan B. Those who chose an IUD had a lower cumulative risk of unintended pregnancy at 1 year.
-
Long-term complications, particularly secondary cancers, were significantly more common in patients receiving whole pelvic radiation (vs brachytherapy alone) for early-stage endometrial cancer.